drugset / Trial / NCT01839279
A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.
Timeline
- Start
- 2013-04
- Primary completion
- 2014-02
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | — |
| Subject | Tizanidine | Small molecule | 2 mg | Oral |
| Subject | Tizanidine | Small molecule | 4 mg | Oral |
Indications
No indication recorded.